keyword
MENU ▼
Read by QxMD icon Read
search

Oral carbapenem

keyword
https://www.readbyqxmd.com/read/29563719/nitrofurantoin-and-fosfomycin-for-extended-spectrum-beta-lactamases-producing-escherichia-coli-and-klebsiella-pneumoniae
#1
Neeraj Kumar Tulara
Urinary tract infection (UTI) is a common and painful human illness that, unfortunately not responsive to commonly used antibiotics in current practice. The role of fosfomycin and nitrofurantoin in the era of growing bacteria resistance has been widely discussed. In this study, we aimed to know the local antimicrobial susceptibilities, fosfomycin and nitrofurantoin susceptibility in particular, for urinary extended-spectrum-beta-lactamase-producing Escherichia coli and Escherichia pneumoniae (ESBL-EC and ESBL-KP) isolates in our hospital...
January 2018: Journal of Global Infectious Diseases
https://www.readbyqxmd.com/read/29549049/the-first-multi-centre-point-prevalence-survey-in-four-japanese-university-hospitals
#2
H Morioka, M Nagao, S Yoshihara, H Ohge, K Kasahara, N Shigemoto, T Kajihara, M Mori, M Iguchi, Y Tomita, S Ichiyama, T Yagi
BACKGROUND: The Japanese government adopted a national action plan on antimicrobial resistance, which aims to reduce drug-resistant pathogens and antimicrobial use. A point-prevalence survey (PPS) is a useful surveillance method to gain information about hospital epidemiology; however, no multi-centre PPS has previously been performed in Japan. AIM: To investigate general information about hospital epidemiology, healthcare-associated infections (HCAIs), and antimicrobial use in multiple Japanese university hospitals...
March 13, 2018: Journal of Hospital Infection
https://www.readbyqxmd.com/read/29514274/treatment-of-infections-caused-by-multidrug-resistant-gram-negative-bacteria-report-of-the-british-society-for-antimicrobial-chemotherapy-healthcare-infection-society-british-infection-association-joint-working-party
#3
Peter M Hawkey, Roderic E Warren, David M Livermore, Cliodna A M McNulty, David A Enoch, Jonathan A Otter, A Peter R Wilson
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and community antimicrobial usage in urinary infection. The international definition of MDR is complex, unsatisfactory and hinders the setting and monitoring of improvement programmes. We give a new definition of multiresistance. The background information on the mechanisms, global spread and UK prevalence of antibiotic prescribing and resistance has been systematically reviewed...
March 1, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29496334/whole-genome-analysis-of-a-multidrug-resistant-streptococcus-pneumoniae-isolate-from-a-patient-with-invasive-pneumococcal-infection-developing-disseminated-intravascular-coagulation
#4
Yasuo Ohkoshi, Toyotaka Sato, Takayuki Wada, Yukari Fukushima, Hiromi Murabayashi, Yasunari Takakuwa, Kaoru Nishiyama, Hiroyuki Honda, Tsukasa Shiraishi, Koji Kuronuma, Hiroki Takahashi, Chie Nakajima, Yasuhiko Suzuki, Shin-Ichi Yokota
Multidrug-resistant Streptococcus pneumoniae strains were isolated from blood and sputum of a patient with disseminated intravascular coagulation in Sapporo city, Japan. These antibiograms were only susceptible to vancomycin, linezolid, daptomycin, some carbapenems, and some fluoroquinolones. Identical antibiograms, serotypes (19F), and sequence types (ST10017) suggested a shared origin of these isolates. Only one ST10017 strain has been isolated in the same city in Japan previously (2014), and the 2014 isolate is still susceptible to macrolides...
February 26, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29491300/emergence-of-carbapenem-non-susceptible-campylobacter-coli-after-long-term-treatment-against-recurrent-bacteremia-in-a-patient-with-x-linked-agammaglobulinemia
#5
Hideharu Hagiya, Keigo Kimura, Isao Nishi, Hisao Yoshida, Norihisa Yamamoto, Yukihiro Akeda, Kazunori Tomono
We herein report a case of recurrent Campylobacter coli bacteremia in a 37-year-old Japanese man with X-linked agammaglobulinemia (XLA). The patient experienced seven episodes of C. coli bacteremia over one year, with an erythematous rash intermittently emerged on the lower limbs. Although hospitalization for intravenous treatment was repeatedly recommended, he obstinately declined it. Following long-term oral antibiotic treatment with tebipenem and faropenem for the persistent infection, C. coli showed elevated minimum inhibitory concentrations to meropenem, a key drug for severe campylobacteriosis...
February 28, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29486041/effect-of-meropenem-vaborbactam-vs-piperacillin-tazobactam-on-clinical-cure-or-improvement-and-microbial-eradication-in-complicated-urinary-tract-infection-the-tango-i-randomized-clinical-trial
#6
Keith S Kaye, Tanaya Bhowmick, Symeon Metallidis, Susan C Bleasdale, Olexiy S Sagan, Viktor Stus, Jose Vazquez, Valerii Zaitsev, Mohamed Bidair, Erik Chorvat, Petru Octavian Dragoescu, Elena Fedosiuk, Juan P Horcajada, Claudia Murta, Yaroslav Sarychev, Ventsislav Stoev, Elizabeth Morgan, Karen Fusaro, David Griffith, Olga Lomovskaya, Elizabeth L Alexander, Jeffery Loutit, Michael N Dudley, Evangelos J Giamarellos-Bourboulis
Importance: Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections. Objective: To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infection (UTI), including acute pyelonephritis. Design, Setting, and Participants: Phase 3, multicenter, multinational, randomized clinical trial (TANGO I) conducted November 2014 to April 2016 and enrolling patients (≥18 years) with complicated UTI, stratified by infection type and geographic region...
February 27, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29370234/febrile-urinary-tract-infection-due-to-extended-spectrum-beta-lactamase-producing-enterobacteriaceae-in-children-a-french-prospective-multicenter-study
#7
Fouad Madhi, Camille Jung, Sandra Timsit, Corinne Levy, Sandra Biscardi, Mathie Lorrot, Emmanuel Grimprel, Laure Hees, Irina Craiu, Aurelien Galerne, François Dubos, Emmanuel Cixous, Véronique Hentgen, Stéphane Béchet, Stéphane Bonacorsi, Robert Cohen
OBJECTIVES: To assess the management of febrile urinary-tract infection (FUTIs) due to extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) in children, the Pediatric Infectious Diseases Group of the French Pediatric Society set up an active surveillance network in pediatric centers across France in 2014. MATERIALS AND METHODS: We prospectively analysed data from 2014 to 2016 for all children < 18 years old who received antibiotic treatment for FUTI due to ESBL-E in 24 pediatric centers...
2018: PloS One
https://www.readbyqxmd.com/read/29327131/renal-vein-thrombosis-complicating-severe-acute-pyelonephritis-with-renal-abscesses-and-associated-bacteraemia-caused-by-extended-spectrum-beta-lactamase-producing-escherichia-coli
#8
Stelios F Assimakopoulos, Pantelis Kraniotis, Charalambos Gogos, Markos Marangos
Acute pyelonephritis might be complicated by the formation of renal and perirenal abscesses and very rarely by renal vein thrombosis, which is a life-threatening condition. The main causative agents of acute pyelonephritis are enterobacteriaceae with the incidence of extended-spectrum beta-lactamase (ESBL)-producing strains increasing worldwide. We present the case of a 71-year-old Greek man with history of diabetes mellitus and recent hospitalization, who suffered from severe pyelonephritis with renal abscesses formation and associated bacteraemia caused by ESBL-producing Escherichia coli, complicated by extensive thrombosis of the ipsilateral renal vein and its branches, protruding also in the inferior venal cava...
May 2018: CEN Case Reports
https://www.readbyqxmd.com/read/29064133/-double-carbapenem-and-oral-fosfomycin-for-the-treatment-of-complicated-urinary-tract-infections-caused-by-bla-ndm-harboring-enterobacteriaceae-in-kidney-transplantation
#9
Rossana Rosa, Susan D Rudin, Laura J Rojas, Andrea M Hujer, Armando Perez-Cardona, Federico Perez, Robert A Bonomo, Octavio Martinez, Lilian M Abbo, Jose F Camargo
Infections with carbapenemase-producing carbapenem-resistant Enterobacteriaceae represent an emergent problem worldwide. Treatment of infections caused by New Delhi metallo-beta-lactamase (NDM)-harboring Enterobacteriaceae is particularly challenging as it frequently involves the use of nephrotoxic agents, which is problematic in kidney transplant recipients and non-renal transplant patients with marginal kidney function. We present two cases of urinary tract infections caused by NDM-harboring Enterobacteriaceae successfully treated with a combination of "double carbapenem" and oral fosfomycin...
February 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29019016/repurposing-zidovudine-in-combination-with-tigecycline-for-treating-carbapenem-resistant-enterobacteriaceae-infections
#10
S M S Ng, J S P Sioson, J M Yap, F M Ng, H S V Ching, J W P Teo, R Jureen, J Hill, C S B Chia
The global emergence of carbapenem-resistant Enterobacteriaceae (CRE) presents a significant clinical concern, prompting the WHO to prioritize CRE as a top priority pathogen in their 2017 global antibiotic-resistant bacteria priority list. Due to the fast-depleting antibiotic arsenal, clinicians are now resorting to using once-abandoned, highly toxic antibiotics such as the polymyxins and aminoglycosides, creating an urgent need for new antibiotics. Drug repurposing, the application of an approved drug for a new therapeutic indication, is deemed a plausible solution to this problem...
January 2018: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/28865741/long-term-outcomes-of-inappropriate-antibiotic-therapy-for-upper-urinary-tract-infections-caused-by-extended-spectrum-beta-lactamase-producing-enterobacteriaceae-a-retrospective-cohort-study
#11
Inbal Greenhouse, Frida Babushkin, Talya Finn, Zvi Shimoni, Moran Aliman, Ronen Ben-Ami, Regev Cohen
BACKGROUND: To evaluate the short- and long-term outcomes of different antimicrobial treatment options for upper urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. METHODS: We retrospectively analyzed patients with a first episode of febrile UTI and positive urine culture with ESBL-producing E. coli or K. pneumoniae during 2012-2015. We compared outcomes among patients who received: (1) definitive treatment with a carbapenem (CP), (2) a microbiologically appropriate intravenous non-carbapenem agent (NCA), (3) a non-appropriate antimicrobial (NAA), and (4) an intravenous NAA followed by an oral NCA (NAA-PO)...
November 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28826769/prevention-of-oprd-regulated-antibiotic-resistance-in-pseudomonas-aeruginosa-biofilm
#12
Raavi, Swechha Mishra, Sangeeta Singh
In P.aeruginosa biofilms, the issue of antibiotic resistance is of particular importance due to increasing number of infections being reported in medical implants. The current study is focused on CzcR and CopR proteins which are part of two-component signal transduction systems (TCSs) - CzcR-CzcS and CopR-CopS respectively in P.aeruginosa. They both negatively regulate OprD porin expression which affects the intake of antibiotics like carbapenems. These two proteins can be treated as targets to combat antibiotic resistance in P...
August 19, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28587974/a-randomized-controlled-trial-of-sitafloxacin-vs-ertapenem-as-a-switch-therapy-after-treatment-for-acute-pyelonephritis-caused-by-extended-spectrum-%C3%AE-lactamase-producing-escherichia-coli-a-pilot-study
#13
RANDOMIZED CONTROLLED TRIAL
Chitprasong Malaisri, Angsana Phuphuakrat, Arrug Wibulpolprasert, Pitak Santanirand, Sasisopin Kiertiburanakul
BACKGROUND: The overuse and misuse of carbapenems have contributed to the antibiotic resistance crisis. The role of oral fluoroquinolones as a switch therapy for the treatment of urinary tract infection from Escherichia coli (ESBL-EC) is limited. OBJECTIVE: To compare the clinical and bacteriological efficacy of sitafloxacin and ertapenem for non-bacteremic acute pyelonephritis caused by ESBL-EC. METHODS: A prospective randomized controlled trial of patients with acute pyelonephritis caused by ESBL-EC was performed as a pilot study...
August 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28555497/ldt-mav2-a-nonclassical-transpeptidase-and-susceptibility-of-mycobacterium-avium-to-carbapenems
#14
Rohini Mattoo, Evan P Lloyd, Amit Kaushik, Pankaj Kumar, Julie L Brunelle, Craig A Townsend, Gyanu Lamichhane
AIM: Mycobacterium avium infections, especially in immune-compromised individuals, present a significant challenge as therapeutic options are limited. In this study, we investigated if M. avium genome encodes nonclassical transpeptidases and if newer carbapenems are effective against this mycobacteria. MATERIALS & METHODS: Biochemical and microbiological approaches were used to identify and characterize a nonclassical transpeptidase, namely L,D-transpeptidase, in M...
June 2017: Future Microbiology
https://www.readbyqxmd.com/read/28513809/oral-gentamicin-therapy-for-carbapenem-resistant-klebsiella-pneumoniae-gut-colonization-in-hematologic-patients-a-single-center-experience
#15
Paola Lambelet, Carlo Tascini, Simona Fortunato, Alessandro Stefanelli, Federico Simonetti, Chiara Vettori, Alessandro Leonildi, Francesco Menichetti
The mortality for carbapenem-resistant Klebsiella pneumoniae (KPC-Kp) infection ranges from 18 to 48% depending on the type of therapy. Mortality rates in hematologic patients are even higher, up to 85%. Gut decontamination with oral gentamicin might be an option to avoid a subsequent KPC-Kp infection in colonized patients. We treated 14 hematologic patients with oral gentamicin, 80 mg four times daily, for 7 to 25 days in order to eradicate KPC-Kp from the gut, starting oral gentamicin therapy when possible after the discontinuation of systemic antibiotic therapy...
July 2017: New Microbiologica
https://www.readbyqxmd.com/read/28499830/implementation-of-a-systematic-culturing-program-to-monitor-the-efficacy-of-endoscope-reprocessing-outcomes-and-costs
#16
Gene K Ma, David A Pegues, Michael L Kochman, Kevin Alby, Neil O Fishman, Marianne Saunders, Carolyn Grous, Daniel T Dempsey, Gregory G Ginsberg
BACKGROUND AND AIMS: In 2015, the U.S. Food and Drug Administration and Centers for Disease Control and Prevention (CDC) issued guidance for duodenoscope culturing and reprocessing in response to outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) duodenoscope-related infections. Based on this guidance, we implemented best practices for reprocessing and developed a systematic process for culturing endoscopes with elevator levers. The aim of this study is to report the outcomes and direct costs of this program...
January 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28469304/fosfomycin-susceptibility-among-multidrug-resistant-extended-spectrum-beta-lactamase-producing-carbapenem-resistant-uropathogens
#17
Sayantan Banerjee, Mallika Sengupta, Tanoy Kumer Sarker
INTRODUCTION: Urinary tract infection (UTI) is one of the most common infectious diseases. With the emergence of multidrug resistance (MDR), therapeutic options for treatment of UTIs are becoming limited. Fosfomycin has emerged as a novel oral therapeutic option with bactericidal activity against the MDR uropathogens. We evaluated the susceptibility pattern of uropathogens to this antibiotic. METHODS: A prospective study was conducted for 6 months in a tertiary care hospital in Eastern India to evaluate whether the common uropathogens were susceptible to fosfomycin...
April 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28390962/in-vitro-activity-of-fosfomycin-trometamol-and-other-oral-antibiotics-against-multidrug-resistant-uropathogens
#18
Maria Lina Mezzatesta, Giulia La Rosa, Gaetano Maugeri, Tiziana Zingali, Carla Caio, Andrea Novelli, Stefania Stefani
Clinical midstream and urinary catheter isolates (n = 106) of extended-spectrum β-lactamase (ESBL)-positive Escherichia coli, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae, Proteus mirabilis and meticillin-resistant Staphylococcus saprophyticus were tested against fosfomycin using the agar dilution method, the broth microdilution method and the gradient test described by the Clinical and Laboratory Standards Institute. Nitrofurantoin, co-trimoxazole, amoxicillin/clavulanic acid, cefuroxime, levofloxacin and ciprofloxacin were tested using the gradient test alone...
June 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28368074/management-of-carbapenem-resistant-k-pneumoniae-in-allogenic-stem-cell-transplant-recipients-the-turin-bundle
#19
Francesco Giuseppe De Rosa, Silvia Corcione, Stefania Raviolo, Benedetto Bruno, Alessandro Busca
Carbapenem resistance has evolved rapidly since 2001 and the distribution of Carbapenemase-producing Klebsiella pneumoniae (CR-Kp) is currently a public health concern worldwide. In the haematological setting, especially in allogenic transplant, CR-KP infections were associated with a mortality up to 65%. Aim of this report is to describe the management of patients colonized by CR-Kp and undergoing allo- HSCT with a multiple-step intervention strategy: the "Turin bundle". Steps included oral gentamicin (GO) within 20 days before allo-HSCT, avoidance of levofloxacin prophylaxis during neutropenia, treatment of febrile neutropenia with tigecycline 100 mg bid and piperacillin-tazobactam at standard dosages and early appropriate combination therapy for patients with severe sepsis...
April 2017: New Microbiologica
https://www.readbyqxmd.com/read/28350901/gram-negative-bacterial-infections-research-priorities-accomplishments-and-future-directions-of-the-antibacterial-resistance-leadership-group
#20
REVIEW
Yohei Doi, Robert A Bonomo, David C Hooper, Keith S Kaye, James R Johnson, Cornelius J Clancy, Joshua T Thaden, Martin E Stryjewski, David van Duin
Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials...
March 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
97290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"